Form 4: DYNAVAX Director Emilio Emini Boosts Stake with Significant Equity Grants

DYNAVAX Technologies Corp. Director Emilio Emini was granted 1,439 restricted stock units and 7,125 stock options on June 11, 2025, increasing his direct beneficial ownership in the company.

Summary

• Emilio Emini, a Director of DYNAVAX Technologies Corp. (DVAX), acquired 1,439 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 11, 2025.
• Each RSU represents a contingent right to receive one share of DVAX Common Stock and will fully vest one year from the grant date, provided Mr. Emini continues to provide services to the company.
• The release of RSU shares will be mandatorily deferred six months and one day after Mr. Emini no longer provides services to the company.
• Mr. Emini also acquired 7,125 stock options with an exercise price of $10.18 per share on June 11, 2025.
• These stock options will fully vest and become exercisable one year from the grant date, contingent on Mr. Emini's continued service to the company.
• The stock options have an expiration date of June 10, 2032.
• Following these transactions, Mr. Emini directly beneficially owns 10,075 shares of Common Stock and 7,125 stock options.
• The transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The grants of restricted stock units and stock options to a director are generally viewed positively as they align the interests of management with those of shareholders, incentivizing long-term company performance. This is a routine compensation event, not indicative of immediate operational changes, but a positive signal for governance and alignment.

Positives

• The acquisition of restricted stock units and stock options by a director indicates a strong alignment of interests between management and shareholders.
• Equity grants are a common form of compensation that incentivizes long-term performance and commitment from key personnel.

Future Outlook

The future outlook for these specific grants is tied to the vesting schedule, with both the Restricted Stock Units and Stock Options set to fully vest one year from the grant date (June 11, 2026), contingent upon the director's continued service to the company. The RSUs also have a mandatory deferral period for release after service termination.

Industry Context

Equity grants, such as Restricted Stock Units and stock options, are a standard and widely adopted component of executive and director compensation packages across various industries, including the biotechnology and pharmaceutical sectors. This practice is designed to align the interests of company leadership with those of shareholders by tying a portion of their compensation to the company's stock performance and long-term value creation.

Comparison to Industry Standards

• The grant of RSUs and stock options to a director is a common form of equity compensation, consistent with practices observed in many publicly traded companies, particularly within the biotechnology and life sciences sectors.
• The vesting schedule of one year for both RSUs and options is a typical short-to-medium term incentive structure, comparable to similar grants at companies like Moderna, BioNTech, or Gilead Sciences, which often use equity to retain and incentivize key talent.
• The use of a Rule 10b5-1 plan for these transactions is a standard compliance measure, demonstrating a pre-arranged trading plan to avoid accusations of insider trading, a practice widely adopted by executives across the S&P 500.

Corporate Governance

Related Party Transactions

• The grants of Restricted Stock Units and Stock Options to Director Emilio Emini constitute a related party transaction, as they involve compensation from the company to a member of its board of directors. This is a standard and disclosed form of compensation.

Stakeholder Impact

• Shareholders: Positive impact due to increased alignment of a director's financial interests with the company's long-term performance and stock value.
• Employees: No direct impact mentioned, but a well-compensated and incentivized board can contribute to overall company stability and success.
• Management: The grants serve as an incentive for the director to contribute to the company's success and long-term value creation.

Next Steps

• The Restricted Stock Units and Stock Options are scheduled to vest one year from the grant date (June 11, 2026), contingent on the director's continued service.

Key Dates

Recommendation

Keywords

DYNAVAX, DVAX, SEC Form 4, Insider Trading, Beneficial Ownership, Restricted Stock Units, RSU, Stock Options, Equity Compensation, Director Compensation, Corporate Governance